Actress Jamie-Lynn Sigler has multiple sclerosis (colloquially known as MS), and that's precisely why she's starring in the ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

Calorie-managed diets and exercise have been the mainstay approach of commercial weight loss programs for decades. But as weight loss medications like Ozempic, Wegovy and others become household ...

Ozempic (semaglutide) and Wegovy (semaglutide) are prescription drugs that may be used to help with long-term weight loss. But only Wegovy is FDA-approved for this use. Both drugs are approved for ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of being considered in shortage by the Food and Drug Administration (FDA).

Rybelsus is an oral form of semaglutide, the active ingredient in the company’s blockbuster Ozempic and Wegovy diabetes and weight-loss drugs, and was tested in the trial on diabetic patients ...

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analog class, better known under the trade names Ozempic and Wegovy, is remarkable ...

Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply ...

Wegovy Q3 sales total $2.5 bln Beat forecast but group sales weaker than expected Results soothe investor worries over slowing obesity drug demand Shares rose nearly 9%, but later reversed course ...

The demand for weight loss operations dropped sharply last year as the number of people opting for anti-obesity drugs such as Wegovy and Saxenda more than doubled, a study published Friday found.